BIO PORT KOREA, INC.

As of June 30, 2026, BIO PORT KOREA, INC. carries a market capitalization of 23.29B, placing it among publicly traded companies globally. Its enterprise value stands at 19.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BIO PORT KOREA, INC.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, BIO PORT KOREA, INC. has 4.61M shares outstanding.

As of June 30, 2026, BIO PORT KOREA, INC. trades at a trailing price-to-earnings ratio of 7.75. The price-to-sales ratio is 0.29, and the price-to-book ratio stands at 0.55.

As of June 30, 2026, BIO PORT KOREA, INC. trades at an EV/EBITDA multiple of 3.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.22 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 19.67B versus a market cap of 23.29B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BIO PORT KOREA, INC. maintains a current ratio of 2.06, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.82, indicating elevated leverage, while an interest coverage ratio of 20.10 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BIO PORT KOREA, INC. posted a return on equity (ROE) of 7.34, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.81, measuring how efficiently the asset base is converted into earnings. The company generates approximately 708.86M in revenue per employee across its workforce of 110.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.67 indicates how many times BIO PORT KOREA, INC. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BIO PORT KOREA, INC. recorded an income tax benefit of -207.44M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 2.76B, leaving 2.96B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, BIO PORT KOREA, INC.'s stock has declined approximately 51.07% over the past 52 weeks. The 50-day moving average sits at 4,997.90, while the 200-day moving average is 5,716.08.

Over the twelve months ended June 30, 2026, BIO PORT KOREA, INC. generated 77.97B in revenue and converted that into 2.96B in net income, yielding earnings per share of 651.80. EBITDA reached 4.99B, while operating income came in at 2.39B.

As of June 30, 2026, BIO PORT KOREA, INC. holds 20.47B in cash and equivalents against 16.85B in total debt, resulting in a net debt position of -2.02B. Total book value stands at 42.32B, with working capital of 22.31B providing operational flexibility.

BIO PORT KOREA, INC. produced -1.77B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.77B in capital expenditures, free cash flow totaled -6.54B - equivalent to -1,439.87 per share.

Over the twelve months ended June 30, 2026, BIO PORT KOREA, INC. posted a gross margin of 24.97, reflecting its pricing power and cost economics. The operating margin of 3.07 and net profit margin of 3.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -28.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.78, meaning BIO PORT KOREA, INC. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BIO PORT KOREA, INC. has an Altman Z-Score of 2.71, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.